Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>/=18 years of age~* early rheumatoid arthritis (disease symptoms \<1 year) according to ACR criteria~* disease activity DAS28 \>2.6~* body weight \</=110kg, BMI \</=36~Exclusion Criteria:~* rheumatic autoimmune disease other than RA~* current inflammatory joint disease other than RA~* previous treatment with any DMARD or biologic drug used in the treatment of RA~* intra-articular, parenteral or oral glucocorticoids used for the arthritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab + Methotrexate (Type: EXPERIMENTAL): Participants will receive intravenous (IV) TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + oral capsules of MTX 10-30 mg/week in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week. The weekly dose of MTX will be taken on one particular day of the week.
- Tocilizumab + Placebo Methotrexate (Type: ACTIVE_COMPARATOR): Participants will receive IV TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + weekly oral matching placebo MTX capsules in climbing dosages. The weekly dose of placebo MTX will be taken on one particular day of the week.
- Methotrexate + Placebo Tocilizumab (Type: ACTIVE_COMPARATOR): Participants will receive weekly oral MTX in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week + matching placebo TCZ IV 8 mg/kg every four week for a maximum of 26 infusions. The weekly dose of MTX will be taken on one particular day of the week.

Based on this trial design, predict the completion outcome and termination type (if applicable).